A new treatment for MSTue, Nov 02, 2010
Madam, – As the national organisation providing information and support to the MS community, we share Godfrey Augustt’s interest (October 11th) in chronic cerebro-spinal venous insufficiency (CCSVI). Over the years we have witnessed many potential and experimental treatments for MS come into focus. While not all of these become significant treatment options, they all play a role in advancing research and improving our understanding of MS.
CCSVI is in the initial stages of research. Dr Paolo Zamboni’s study showed very strong evidence to suggest a link between the narrowing of veins and MS. However, subsequent research conducted, using more standard protocols, has not showed the same results. Two German and one Swedish study indicated little statistical difference between the presence of narrow veins among those with MS and those without.
The research now available proves only one thing; that more research is needed.
There are 8,000 people with MS in Ireland and each uses various treatments, interventions and techniques to manage MS. We believe in free choice and our role is to provide enough information for people to make their own decisions about their treatment options. We encourage people to read, research and speak to their healthcare team. However, we do encourage a person to be cautious about any treatment or technique that has not yet been proven to be safe or effective in the treatment of MS. At all times we want to protect the health and well-being of people with MS and their families.
In relation to Mr Augustt’s assertion that MS Societies receive “huge amounts of money” to advertise pharmaceutical products, I can say that this is not the case in MS Ireland. Under the Irish Pharmaceutical Healthcare Association’s guidelines, we cannot advertise products on a pharmaceutical’s behalf. We do not promote any pharmaceutical other than giving standard information on all products to facilitate the decision making process of people with MS.
The contribution we get from the pharmaceuticals, which is all unrestricted, accounts for 4 per cent of our annual income. It is spent on our core services such as our information services, care centres, home visit services and counselling. Our website www.ms-society.ie carries further information about CCSVI. – Yours, etc,
Multiple Sclerosis Ireland,